BFRI

Biofrontera Inc. (BFRI) | Rumor.io

Biofrontera

BFRI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,275

Bullish sentiment (50-day avg)91%

Price to earnings ratio0.89

Market capitalization16.8M

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)41.7M

Net income (annual)-10.5M

Social

What share of all stock conversation is about BFRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 15

Biofrontera Inc. ($BFRI) received FDA approval for Ameluz, a treatment for superficial basal cell carcinoma, expanding its dermatology market.
The company's stock price plummeted despite having a strong path to financial success, with some investors questioning their decision not to buy more shares.
Biofrontera's treatment for cancer is expected to be in high demand, particularly among fair-skinned baby boomers who will need it, and some investors believe it could be a steal.

Generated by AI

Sentiment

Of the messages about BFRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	72.22% -9.26	86.18% -13.04	92.51% +7.38
Bearish	100% 0	27.78% +9.26	13.82% +13.04	7.49% -7.38

Bullish· Sep 14

Biofrontera Inc. has received FDA approval for Ameluz Red Light PDT, a treatment for superficial basal cell carcinoma, which could lead to increased revenue and profitability.
The company's financials are improving, with a gross margin of ~80% and adjusted EBITDA of approximately -$0.2M, indicating a healthier business.
Biofrontera's existing infrastructure and revenue streams, combined with the FDA approval, make it an attractive investment opportunity, despite concerns about its cash situation.

Bearish· Jan 8

Biofrontera Inc. ($BFRI) is being manipulated by market makers and dark pools, suppressing its price despite strong buying interest.
The company's stock is being artificially held down by a combination of short selling and manipulative trading practices, preventing it from reaching its true value.
A significant short position in the stock is being held by a hedge fund or market maker, which is causing the price to be artificially depressed and is likely to be closed out when the truth about the company's success is revealed.

Generated by AI

Topics

Of the messages about BFRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	27.81%	75.8%
Technical Analysis	—	25%	36.69%	12.69%
Controversies	—	0%	2.96%	0.71%
Earnings	—	0%	0%	1.42%
Macro	—	0%	32.54%	7.95%
Analysts	—	0%	0%	1.42%

Analysts· Dec 15

Benchmark initiated coverage on Biofrontera with a Buy rating and announced a price target of $11.
Analysts are confident about Biofrontera, with a 83% buy consensus among 7 analysts.
Biofrontera shares closed up 26% at $6.95 after Benchmark initiated coverage with a Buy rating and announced a price target of $11.

Announcements· Feb 9

Biofrontera Inc. (BFRI) announced positive results in a Phase 3 study of Ameluz PDT for actinic keratoses on the extremities, neck, and trunk, meeting the primary endpoint.
The study's positive outcome is expected to expand the use-case for Ameluz PDT, driving short-term excitement in the market despite recent negative price momentum.
Biofrontera plans to submit a supplemental New Drug Application (sNDA) based on the Phase 3 study results, which could lead to further market opportunities for the company.

Technical Analysis· Oct 31

$BFRI has been consolidating and may be ready for the next leg up, with a potential break above $1.68 filling a $4 gap.
The stock has formed a bull flag and bounced off a big support line, with entries available above $1.60+.
A double bottom has formed, with a gap filled, and the stock is holding, with a potential break above $1.68 triggering a new high.

Generated by AI

Community

Of the messages about BFRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	23.08%	16.06%	47.95%
Newcomers	100%	76.92%	83.94%	52.05%

Regulars· Sep 11

The FDA has approved a label update for Ameluz concerning hypersensitivity/allergic reactions, with some interpreting this as a positive sign for the product's approval on September 28th.
The company's own investor page still lists the FDA approval as being for actinic keratosis, not superficial basal cell carcinoma (sBCC), which may indicate that the approval process is not yet complete.
The FDA's approval of the label update does not necessarily mean that the product will be approved on September 28th, and some are advising caution and waiting for further confirmation before making investment decisions.

Newcomers· Sep 15

Many newcomers are focused on the potential for a buyout, with some expressing a desire to see the stock price increase due to this possibility.
Some are concerned about the company's near-term financials, citing near breakeven point and potential dilution, and are waiting to see how the stock price will hold up.
Newcomers are also tracking the stock's support levels, with some noting that the price point of $1.19 is a significant resistance point and potential target for a rebound.

Generated by AI

On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

1d agoBenzinga

Biofrontera stock gets FDA approval for skin cancer treatment

14d agoInvesting.com

Biofrontera wins FDA approval for Ameluz to treat skin cancer

15d agoInvesting.com

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Detailed price information for Biofrontera Inc (BFRI-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Biofrontera Inc. Q2 2026 Earnings Call Summary

Moby summary of Biofrontera Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...

Biofrontera Inc (BFRI) reports a 45% jump in Ameluz prescriptions and improved gross margins, while navigating competitive pressures and a widened net loss in Q2 2026.

1mo agoYahoo Finance

Also Discussed

Investors talking about BFRI also mention

#	Name	Attention
1	Longeveron Inc. Class A Common StockLGVN	0%0
2	PTPI - Petros Pharmaceuticals, Inc.	——
3	Society Pass IncorporatedSOPA	0%0
4	iSpecimen Inc.ISPC	0%0
5	Pasithea Therapeutics Corp.KTTA	0%0
6	Context Therapeutics Inc.CNTX	0%0
7	Immix Biopharma, Inc.IMMX	0.03%+0.03
8	Ensysce Biosciences, Inc. Common StockENSC	0%0
9	Pioneer Power Solutions Inc.PPSI	0%new
10	ALLK - Allakos Inc.	——

Biofrontera Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy. Its commercial portfolio centers on Ameluz, a prescription topical gel used together with BF-RhodoLED and RhodoLED lamp systems for the treatment of actinic keratoses, a common precancerous skin condition. The company also markets Xepi, a topical antibiotic for impetigo, expanding its presence in prescription skin care. Biofrontera works directly with dermatology practices and specialist groups, supporting clinical use through products designed for office-based treatment settings. Headquartered in Woburn, Massachusetts, Biofrontera plays a niche role in the dermatology market by combining drug and device-based therapies for targeted skin treatment.

Website

Location

660 Main Street

Woburn, MA, 01801

United States

Social

What share of all stock conversation is about BFRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 15

Biofrontera Inc. ($BFRI) received FDA approval for Ameluz, a treatment for superficial basal cell carcinoma, expanding its dermatology market.
The company's stock price plummeted despite having a strong path to financial success, with some investors questioning their decision not to buy more shares.
Biofrontera's treatment for cancer is expected to be in high demand, particularly among fair-skinned baby boomers who will need it, and some investors believe it could be a steal.

Generated by AI

Sentiment

Of the messages about BFRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	72.22% -9.26	86.18% -13.04	92.51% +7.38
Bearish	100% 0	27.78% +9.26	13.82% +13.04	7.49% -7.38

Bullish· Sep 14

Biofrontera Inc. has received FDA approval for Ameluz Red Light PDT, a treatment for superficial basal cell carcinoma, which could lead to increased revenue and profitability.
The company's financials are improving, with a gross margin of ~80% and adjusted EBITDA of approximately -$0.2M, indicating a healthier business.
Biofrontera's existing infrastructure and revenue streams, combined with the FDA approval, make it an attractive investment opportunity, despite concerns about its cash situation.

Bearish· Jan 8

Biofrontera Inc. ($BFRI) is being manipulated by market makers and dark pools, suppressing its price despite strong buying interest.
The company's stock is being artificially held down by a combination of short selling and manipulative trading practices, preventing it from reaching its true value.
A significant short position in the stock is being held by a hedge fund or market maker, which is causing the price to be artificially depressed and is likely to be closed out when the truth about the company's success is revealed.

Generated by AI

Topics

Of the messages about BFRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	27.81%	75.8%
Technical Analysis	—	25%	36.69%	12.69%
Controversies	—	0%	2.96%	0.71%
Earnings	—	0%	0%	1.42%
Macro	—	0%	32.54%	7.95%
Analysts	—	0%	0%	1.42%

Analysts· Dec 15

Benchmark initiated coverage on Biofrontera with a Buy rating and announced a price target of $11.
Analysts are confident about Biofrontera, with a 83% buy consensus among 7 analysts.
Biofrontera shares closed up 26% at $6.95 after Benchmark initiated coverage with a Buy rating and announced a price target of $11.

Announcements· Feb 9

Biofrontera Inc. (BFRI) announced positive results in a Phase 3 study of Ameluz PDT for actinic keratoses on the extremities, neck, and trunk, meeting the primary endpoint.
The study's positive outcome is expected to expand the use-case for Ameluz PDT, driving short-term excitement in the market despite recent negative price momentum.
Biofrontera plans to submit a supplemental New Drug Application (sNDA) based on the Phase 3 study results, which could lead to further market opportunities for the company.

Technical Analysis· Oct 31

$BFRI has been consolidating and may be ready for the next leg up, with a potential break above $1.68 filling a $4 gap.
The stock has formed a bull flag and bounced off a big support line, with entries available above $1.60+.
A double bottom has formed, with a gap filled, and the stock is holding, with a potential break above $1.68 triggering a new high.

Generated by AI

Community

Of the messages about BFRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	23.08%	16.06%	47.95%
Newcomers	100%	76.92%	83.94%	52.05%

Regulars· Sep 11

The FDA has approved a label update for Ameluz concerning hypersensitivity/allergic reactions, with some interpreting this as a positive sign for the product's approval on September 28th.
The company's own investor page still lists the FDA approval as being for actinic keratosis, not superficial basal cell carcinoma (sBCC), which may indicate that the approval process is not yet complete.
The FDA's approval of the label update does not necessarily mean that the product will be approved on September 28th, and some are advising caution and waiting for further confirmation before making investment decisions.

Newcomers· Sep 15

Many newcomers are focused on the potential for a buyout, with some expressing a desire to see the stock price increase due to this possibility.
Some are concerned about the company's near-term financials, citing near breakeven point and potential dilution, and are waiting to see how the stock price will hold up.
Newcomers are also tracking the stock's support levels, with some noting that the price point of $1.19 is a significant resistance point and potential target for a rebound.

Generated by AI

Biofrontera

Social

Sep 15

Bullish· Sep 14

Bearish· Jan 8

Analysts· Dec 15

Announcements· Feb 9

Technical Analysis· Oct 31

Regulars· Sep 11

Newcomers· Sep 15

Transcript: Biofrontera Q2 2026 Earnings Conference Call - Biofrontera (NASDAQ:BFRI)

Biofrontera stock gets FDA approval for skin cancer treatment

Biofrontera wins FDA approval for Ameluz to treat skin cancer

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. Q2 2026 Earnings Call Summary

Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...

Also Discussed

Biofrontera Inc.

Company Information

Location

Transcript: Biofrontera Q2 2026 Earnings Conference Call - Biofrontera (NASDAQ:BFRI)

Biofrontera stock gets FDA approval for skin cancer treatment

Biofrontera wins FDA approval for Ameluz to treat skin cancer

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. Q2 2026 Earnings Call Summary

Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...

Also Discussed

Social

Sep 15

Bullish· Sep 14

Bearish· Jan 8

Analysts· Dec 15

Announcements· Feb 9

Technical Analysis· Oct 31

Regulars· Sep 11

Newcomers· Sep 15